183 related articles for article (PubMed ID: 36162338)
21. CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis.
Marastoni D; Foschi M; Eccher C; Crescenzo F; Mazziotti V; Tamanti A; Bajrami A; Camera V; Ziccardi S; Guandalini M; Bosello F; Anni D; Virla F; Turano E; Romoli M; Mariotti R; Pizzini FB; Bonetti B; Calabrese M
Front Immunol; 2024; 15():1343892. PubMed ID: 38404586
[TBL] [Abstract][Full Text] [Related]
22. Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States.
Song Y; Wang Y; Wong SL; Yang D; Sundar M; Tundia N
Mult Scler Relat Disord; 2023 Nov; 79():105052. PubMed ID: 37832254
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
24. Safety and Effectiveness of Cladribine in Multiple Sclerosis: Real-World Clinical Experience From 5 Tertiary Hospitals in Portugal.
Santos M; Sequeira J; Abreu P; Guerreiro R; Santos M; Ferreira J; Brum M; Ladeira F; Leitão L; Dias R; Sá MJ; Salgado V; Capela C; de Sá J
Clin Neuropharmacol; 2023 May-Jun 01; 46(3):105-111. PubMed ID: 37191564
[TBL] [Abstract][Full Text] [Related]
25. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis.
Piasecka-Stryczyńska K; Kaczyński Ł; Rolka M; Homa M; Staśkiewicz W; Paczwa P; Wójcik R; Kaczor MP; Rejdak K
Neurol Neurochir Pol; 2022; 56(6):480-489. PubMed ID: 36421066
[TBL] [Abstract][Full Text] [Related]
26. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
[TBL] [Abstract][Full Text] [Related]
27. High persistence and low adverse events burden in cladribine treated MS patients from Argentina.
Negrotto L; Iut VC; Etchepare A; D'Eramo M; Grinspan A; Assefi A
Mult Scler Relat Disord; 2022 Dec; 68():104403. PubMed ID: 36544327
[TBL] [Abstract][Full Text] [Related]
28. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
29. Cladribine in aggressive forms of multiple sclerosis.
Martinez-Rodriguez JE; Cadavid D; Wolansky LJ; Pliner L; Cook SD
Eur J Neurol; 2007 Jun; 14(6):686-9. PubMed ID: 17539951
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop).
Schiavetti I; Signori A; Albanese A; Frau J; Cocco E; Lorefice L; di Lemme S; Fantozzi R; Centonze D; Landi D; Marfia G; Signoriello E; Lus G; Zecca C; Gobbi C; Iodice R; Malimpensa L; Cordioli C; Ferraro D; Ruscica F; Pasquali L; Repice A; Immovilli P; Ferrò MT; Bonavita S; Di Filippo M; Abbadessa G; Govone F; Sormani MP;
Eur J Neurol; 2024 Jun; 31(6):e16250. PubMed ID: 38549186
[TBL] [Abstract][Full Text] [Related]
31. A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience.
Alroughani R; AlMojel M; Al-Hashel J; Ahmed SF
Mult Scler Relat Disord; 2023 Jun; 74():104712. PubMed ID: 37054581
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; Verdun di Cantogno E
Mult Scler; 2023 May; 29(6):719-730. PubMed ID: 37012898
[TBL] [Abstract][Full Text] [Related]
33. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.
Rauma I; Viitala M; Kuusisto H; Atula S; Sipilä JOT; Ryytty M; Soilu-Hänninen M; Järvinen E
Mult Scler Relat Disord; 2022 May; 61():103755. PubMed ID: 35483129
[TBL] [Abstract][Full Text] [Related]
34. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B
Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
[TBL] [Abstract][Full Text] [Related]
35. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
[TBL] [Abstract][Full Text] [Related]
36. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
[TBL] [Abstract][Full Text] [Related]
37. Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA).
Alroughani R; AlKawi Z; Hassan A; Al Otaibi H; Mujtaba A; Al Atat R; Riachi N; Akkawi N; Koussa S; Inshasi J; Alsaadi T; Ahmed SF; Al-Aasmi A; Zakaria M; El Fadally H
Clin Neurol Neurosurg; 2021 Apr; 203():106576. PubMed ID: 33714799
[TBL] [Abstract][Full Text] [Related]
38. Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
Giovannoni G; Singer BA; Issard D; Jack D; Vermersch P
Mult Scler; 2022 Jul; 28(8):1219-1228. PubMed ID: 34634968
[TBL] [Abstract][Full Text] [Related]
39. No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany.
Huhn K; Senger D; Utz KS; Schmidt M; Fröhlich K; Waschbisch A; Seifert F; Dörfler A; Lee DH; Linker RA
Mult Scler Relat Disord; 2019 Jan; 27():133-138. PubMed ID: 30384198
[TBL] [Abstract][Full Text] [Related]
40. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L; Annovazzi P; Boffa L; Buscarinu MC; Gallo A; Matta M; Moiola L; Musu L; Perini P; Avolio C; Barcella V; Bianco A; Farina D; Ferraro E; Pontecorvo S; Granella F; Grimaldi LME; Laroni A; Lus G; Patti F; Pucci E; Pasca M; Sarchielli P;
J Neurol; 2018 Dec; 265(12):2851-2860. PubMed ID: 30259178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
